Previously reported pivotal trials on sodium-glucose cotransporter-2 inhibitors (SGLT2is) in heart failure (HF) patients with reduced and preserved ejection fraction, combined with the current findings, support the consistent benefit of SGLT2is across all heart failure presentations, regardless of ...
To date, various oral anti-diabetic drugs have been developed, of which, the sodium glucose transporter-2 inhibitors (SGLT2Is) are of the most recent classes that have been introduced. They differ from other classes in terms of their novel mechanism of actions and unique beneficial effects ...
Subcutaneous insulin via a basal-bolus regimen, where possible, in hospitalized patients, with continuous insulin drip if in an ICU setting are the preferred methods to control blood glucose levels. Oral agents especially metformin and SGLT2 inhibitors should likely be stopped. Biguanides, of which...
The impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on atherosclerosis has been documented to be one of attenuation. Intestinal flora is posited to have an effect on the process of atherosclerosis progression. Our investigation explored whether SGLT2i could ameliorate atherosclerosis by ...
an elevated risk of acute kidney injury, and an extended hospital stay in contrast to non-SGLT2i-related episodes. The substantial advantages of SGLT2 inhibitors, when contrasted with their potential risks, necessitate heightened awareness among healthcare professionals and patients regarding this associ...
through meta-analysis, observed that SGLT2i may reduce EAT over six months [42]. However, in our study, the LVRR group showed an increase in EAT without significant changes in subcutaneous or visceral fat, likely due to the study period (February 2016 to June 2020), when fewer patients ...
The average age stood at 5911 years, with 17416 (an impressive 623%) of the participants being male. After a median observation time of 29 years, the analysis concluded. SGLT2 inhibitors were linked to fewer intensive care unit (ICU) admissions (286 [28%] versus 645 [37%]; hazard ratio...
have shifted the treatment of HF with reduced ejection fraction (HFrEF) towards quadruple therapy: an angiotensin receptor-neprilysin inhibitor or an angiotensin-converting enzyme inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist and a sodium/glucose co-transporter-2 inhibitor (SGLT2i)....
The sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin, benefited from the development of its ester prodrug, dapagliflozin formate (DAP-FOR, DA-2811), designed to improve stability and the pharmaceutical manufacturing process.To determine the pharmacokinetic and safety parameters of ...
SGLT2i Emerges as an Anti-HF Drug in the “Fantastic Four” [91]: Call for Action Real-world studies are useful to examine the degree to which extent the results from RCTs could apply to patients outside the trials and also to assess long-term response and safety. The Comparative Effect...